F	PARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							
(REV. 10-2003)	ATTORNEY'S DOCKET NUMBER							
TRANSMITTAL LETTER TO THE UNITED STATES		4518-0108PUS1						
DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
CONCERNING A FILING UNDER 35 U.S.C. 371		10/524520						
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/AT03/00219	31 July 2003	12 August 2002						
TITLE OF INVENTION	31 0dly 2003	12 August 2002						
USE OF ANTIBODIES AGAINST TUMOR-ASSOCIATED ANTIGEN								
APPLICANT(S) FOR DO/EO/US								
LOIBNER, Hans; HIMMLER, Gottfired; SAMMONIGG, Hellmut; STERMETZ, Eugen; HAUER, Andreas; REDL, Gerda								
Applicant herewith submits to the United States	Designated/Elected Office (DO/EO/US) the following	owing items and other information:						
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include								
items (5), (6), (9) and (21) indicated below.								
4. The US has been elected (Article 31).								
5. A copy of the International Applicati	on as filed (35 U.S.C. 371(c)(2))							
a. 🔀 . is attached hereto (required	only if not transmitted by the International Bu	reau).						
b. has been communicated by t								
c. is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
a. is attached hereto.								
	ted under 35 U.S.C. 154(d)(4)							
	ernational Application under PCT Article 19 (3							
_	a. are attached hereto (required only if not communicated by the International Bureau).							
b. have been communicated by the International Bureau.								
c. have not been made; however, the time limit for making such amendments has NOT expired.								
d. Mave not been made and will not be made.								
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
a. is attached hereto.								
b. has been submitted to the Internal Bureau (See Box VIII-4-1 of the Request (PCT/R0/101), copy attached).								
The Power of Attorney or Authorization of Agent and Certificate under 37 CFR 3.73(b) Showing Chain of Title are: Attached hereto. will follow.								
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11. to 20. below concern document(s) or information included:								
	or information included: t under 37 CFR 1.97 and 1.98, Form PTO-1449	(O/-) and Intermetional Second Depart						
(PCT/ISA/210) with 0 cited documen	. under 3 / CFK 1.9 / and 1.90, FOIIII F 10-144: at(e)	9(s), and international Search Report						
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
3. A preliminary amendment.								
14. An Application Data Sheet								
15. A substitute specification.								
6. A power of attorney and/or change of address letter.								
7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.								
8. A second copy of the published international application under 35 U.S.C. 154(d)(4).								
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
20. Other items or information:								
Four (4) Sheets of Formal Drawings								
Express Mail Certificate (Label No. E	EV 592977371US)							

U.S. APPLICATION NO (if known, see 37 (プロンドスンロ	INTERNATIONAL APPLICATION NO			ATTORNEY'S DOCKET NUMBER			
TA	1.5. APPLICATION NO (# INDICATION NO PCT/AT03/00219			4518-0108PUS1				
BASIC NATI Neither internation and Internation Basic National National Stage	fees are submitted: ONAL FEE (37 CFF ational preliminary ex- tal search fee (37 CFR that search Report not Stage Fee Examination Fee	CAL	<u>CULATIONS</u>	PTO USE ONLY				
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$950.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO								
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$750.00								
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$	950.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 30								
months from the earlies				\$				
SHEETS OF SPEC & DWG	27 -100 = 0	0 x 250 =	\$0	\$	ı			
CLAIMS	NUMBER FILE	D NUMBER EXT				•		
Total Claims	16 - 20 =		x \$50.00	\$				
Independent Claims	2 - 3 =		x \$200.00	\$				
MULTIPLE DEPENDI	ENT CLAIM(S) (if ap	plicable)	+ \$360.00	\$	360.00			
TOTAL OF ABOVE CALCULATIONS =				\$	1310.00			
Applicant claims small entity status. See 37 C.F.R. § 1.27. The fees indicated above are reduced by 1/2.			\$	-655.00	-			
SUBTOTAL =					655.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).				\$		•		
TOTAL NATIONAL FEE =					655.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$				
TOTAL FEES ENCLOSED =					655.00			
				, <i>I</i>	Amount to be: refunded	\$		
ļ	·				charged	\$		
 a. A check in the amount of \$0.00 to cover the above fees is enclosed. b. Please charge my Deposit Account. No. 02-2448 in the amount of \$655.00 to cover the above fees. A duplicate copy of this sheet is enclosed. 								
c. The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Deposit Account No. 02-2448.								
NOTE: Where an appropriate time limit under 37 C.F.R. § 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
Send all correspondence to: Birch, Stewart, Kolasch & Birch, LLP or Customer No. 02292 P.O. Box 747 Falls Church, VA 22040-0747 (714) 708-8555								
Date: February 11,	2005		Ry JA	Dr.	m	-		
Leonard R. Svensson, #30,330								

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT COOPERATION TREATY

APPLICANT:

LOIBNER, Hans et al.

INTERNATIONAL

APPLN. NO.:

PCT/AT03/00219

U.S. APPLN. NO.:

NEW ·

FILING DATE:

11 February, 2005

TITLE:

USE OF ANTIBODIES AGAINST TUMOR-ASSOCIATED

ANTIGEN

DOCKET:

4518-0108PUS1

EXPRESS MAIL CERTIFICATE

DATE DEPOSITED: 11 February, 2005

I hereby certify that the enclosed <u>Transmittal Letter to the United States</u> <u>Designated/Elected Office (DO/EO/US) Concerning A Filing Under 35 U.S.C. 371 and related documents</u> are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-0145.

Express Mail Label No. EV592977371US

Date: 11 February, 2005

Lori M. Tillman

Mailing Address:

Birch, Stewart, Kolasch & Birch, LLP P.O. Box 747 Falls Church, VA 22040-0747 (714) 708-8555